This brand name is authorized in Lithuania, United States
The drug RYZNEUTA contains one active pharmaceutical ingredient (API):
|
1
Efbemalenograstim alfa
UNII 5UPW5HJW3O - EFBEMALENOGRASTIM ALFA
|
|
Human granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Efbemalenograstim alfa is a recombinant fusion protein containing G-CSF, a 16 amino-acid linker, and the Fc portion of human IgG2. Efbemalenograstim alfa is a sustained duration form of G-CSF due to decreased renal clearance. Efbemalenograstim alfa and other G-CSFs have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| RYZNEUTA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RYZNEUTA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L03AA18 | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: LT | Valstybinฤ vaistลณ kontrolฤs tarnyba | Identifier(s): 1099363 |
| Country: US | FDA, National Drug Code | Identifier(s): 73491-627 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
